Literature DB >> 31158113

Cognitive deficit in schizophrenia: an overview.

Alma Mihaljević-Peleš1, Maja Bajs Janović, Marina Šagud, Maja Živković, Špiro Janović, Saša Jevtović.   

Abstract

Depressive mood, anxiety, delusions, hallucinations and behavioral disturbances have been traditionally recognized as leading symptoms of mental disorders. However, cognitive symptoms went under-recognized or declined. Today there is robust evidence that cognitive dysfunction is present in the majority of mental disorders and is also related to impairments in the functioning of the persons with mental illness. It is proposed that aberrant brain neuronal network connectivity, arising from interplay of genetic, epigenetic, developmental and environmental factors, is responsible for cognitive decline. In schizophrenia, dysfunctions in working memory, attention, processing speed, visual and verbal learning with substantial deficit in reasoning, planning, abstract thinking and problem solving have been extensively documented. Social cognition - the ability to correctly process information and use it to generate appropriate response in situations, is also impaired. The correlation of cognitive impairment with functional outcome and employment, independent living and social functioning has emphasized the need for development of the treatments specific to cognition. It is considered that brain neuroplasticity allows for re-modulating and compensating the impairment process which could give opportunity to improve cognitive functions. Therefore, there is a need for comprehensive clinical assessment and follow-up of cognitive decline in mental illness. Implementation of specific treatment strategies addressing cognitive decline in mental illness, like new drugs, distinct cognitive-behavioural therapy, psychoeducation, social skills training and remediation strategies should be strongly indorsed targeting recovery and reduction of disability due to mental illness.

Entities:  

Mesh:

Year:  2019        PMID: 31158113

Source DB:  PubMed          Journal:  Psychiatr Danub        ISSN: 0353-5053            Impact factor:   1.063


  11 in total

1.  Patient Journey of Veterans with Schizophrenia: An Analysis of Treatment Patterns, Healthcare Resource Utilization and Costs.

Authors:  Charmi Patel; Ahong Huang; Li Wang; Yoshita Paliwal; Kruti Joshi
Journal:  Adv Ther       Date:  2022-01-07       Impact factor: 3.845

Review 2.  Neurobiological Highlights of Cognitive Impairment in Psychiatric Disorders.

Authors:  Anna Morozova; Yana Zorkina; Olga Abramova; Olga Pavlova; Konstantin Pavlov; Kristina Soloveva; Maria Volkova; Polina Alekseeva; Alisa Andryshchenko; Georgiy Kostyuk; Olga Gurina; Vladimir Chekhonin
Journal:  Int J Mol Sci       Date:  2022-01-22       Impact factor: 5.923

3.  Sex differences in association between cognitive impairment and clinical correlates in Chinese patients with first-episode drug-naïve schizophrenia.

Authors:  Na Zhao; Xiao Hong Wang; Chuan Yi Kang; Yue Zheng; Li Ying Yang; Tie Feng Guan; Yun Xia Bai; Ran Wei; Hunter C Hinman; Xiang Yang Zhang
Journal:  Ann Gen Psychiatry       Date:  2021-04-21       Impact factor: 3.455

4.  Association of visual motor processing and social cognition in schizophrenia.

Authors:  Pin-Yen Lu; Yu-Lien Huang; Pai-Chuan Huang; Yi-Chia Liu; Shyh-Yuh Wei; Wei-Yun Hsu; Kao Chin Chen; Po See Chen; Wen-Chen Wu; Yen Kuang Yang; Huai-Hsuan Tseng
Journal:  NPJ Schizophr       Date:  2021-04-13

5.  Effects of Mindfulness-Based Stress Reduction (MBSR) on Stress, Heart Rate Variability, Affect, and Wellbeing among People with Schizophrenia.

Authors:  Ae Sil Kim; Mi Heui Jang; Min Jung Sun
Journal:  Int J Environ Res Public Health       Date:  2021-11-12       Impact factor: 3.390

6.  Aberrant cortical surface and cognition function in drug-naive first-episode schizophrenia.

Authors:  Qianqian Wei; Wei Yan; Rongrong Zhang; Xuna Yang; Shiping Xie
Journal:  Ann Gen Psychiatry       Date:  2022-02-10       Impact factor: 3.455

7.  Prevalence, profile and associations of cognitive impairment in Ugandan first-episode psychosis patients.

Authors:  Emmanuel K Mwesiga; Reuben Robbins; Dickens Akena; Nastassja Koen; Juliet Nakku; Noeline Nakasujja; Dan J Stein
Journal:  Schizophr Res Cogn       Date:  2021-12-30

8.  Correlation Between Resting Theta Power and Cognitive Performance in Patients With Schizophrenia.

Authors:  Yanxiang Cao; Chuanliang Han; Xing Peng; Ziyao Su; Gan Liu; Yixi Xie; Yiting Zhang; Jun Liu; Pei Zhang; Wen Dong; Michel Gao; Sha Sha; Xixi Zhao
Journal:  Front Hum Neurosci       Date:  2022-04-22       Impact factor: 3.169

9.  The association of cognitive impairment with quality of life and functional impairment in Ugandan first-episode psychosis patients: a cross sectional study.

Authors:  Emmanuel K Mwesiga; Andrew S Ssemata; Joy Gumikiriza; Angel Nanteza; Anne Jacqueline Nakitende; Juliet Nakku; Dickens Akena; Noeline Nakasujja
Journal:  Health Qual Life Outcomes       Date:  2022-07-23       Impact factor: 3.077

10.  The Gender-Specific Association of DRD2 Polymorphism with Metabolic Syndrome in Patients with Schizophrenia.

Authors:  Diana Z Paderina; Anastasiia S Boiko; Ivan V Pozhidaev; Irina A Mednova; Anastasia A Goncharova; Anna V Bocharova; Olga Yu Fedorenko; Elena G Kornetova; Arkadiy V Semke; Nikolay A Bokhan; Anton J M Loonen; Svetlana A Ivanova
Journal:  Genes (Basel)       Date:  2022-07-23       Impact factor: 4.141

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.